Name
*
First Name
Last Name
Degree(s)
*
Country
*
1. Which statement best describes the pharmacologic rationale for targeting factor XIa (FXIa) rather than factor Xa or thrombin in stroke prevention for atrial fibrillation (SPAF)?
*
FXIa inhibitors act as direct thrombin antagonists that prevent fibrin cross-linking, similar in mechanism to dabigatran but with a longer plasma half-life
FXIa inhibitors potentiate antithrombin III activity to indirectly suppress multiple clotting factors, comparable to the mechanism of unfractionated heparin
FXIa inhibitors interrupt thrombin amplification within the intrinsic pathway while largely sparing the tissue factor-driven hemostatic pathway, aiming to dissociate antithrombotic effect from bleeding risk
FXIa inhibitors block the common pathway shared by both the intrinsic and extrinsic systems, functioning downstream in a manner similar to how apixaban inhibits factor Xa
2. What was the key finding in the phase 3 OCEANIC-AF trial (asundexian vs. apixaban in AF) that led to early termination?
*
Asundexian showed significantly higher rates of stroke or systemic embolism than apixaban despite a lower bleeding rate, prompting early termination by the DSMB
Asundexian met noninferiority for stroke prevention compared with apixaban while also significantly reducing major bleeding, supporting an early regulatory filing
Asundexian was discontinued after Phase 2 due to a hepatotoxicity signal identified during dose-ranging pharmacokinetic studies
Asundexian and apixaban produced statistically indistinguishable rates of both stroke and bleeding, leading investigators to describe the trial as a pragmatic equipoise
3. Which patient profile would most likely be considered a favorable candidate for an FXIa inhibitor over a DOAC for SPAF, should one become available with an appropriate efficacy/safety profile?
*
A 58-year-old with paroxysmal AF, no bleeding history, normal renal function, and a low HAS-BLED score who values dosing convenience
A newly diagnosed AF patient with excellent medication adherence, no comorbidities, and a preference for generic medications
A patient stable on warfarin for 10 years with a therapeutic time in range above 75% and no bleeding events
An 84-year-old frail patient with prior major GI bleeding, an elevated HAS-BLED score, and stage 4 chronic kidney disease who has been left untreated due to bleeding concerns
4. Which patient characteristic profile most strongly supports considering an FXIa inhibitor once available, based on data such as AZALEA-TIMI 71 (62-69% reduction in major/CRNM bleeding vs. rivaroxaban)?
*
A patient with well-controlled hypertension who has no other cardiovascular risk factors beyond an AF diagnosis
A patient with a mechanical mitral valve who requires tightly monitored warfarin dosing rather than a DOAC or novel oral agent
A patient on dual antiplatelet therapy following recent coronary stenting who experienced a clinically relevant nonmajor bleed while on a DOAC
A patient with AF, no hypertension, diabetes, or vascular disease, and no bleeding history to date
5. A 79-year-old woman with AF, CHA2DS2-VASc score of 5 (CHA2DS2-VA=4), HAS-BLED score of 4, and a prior intracranial hemorrhage on warfarin has gone untreated for a year due to bleeding concerns. Which statement best reflects an evidence-based application of current data to her care?
She should start a DOAC immediately since her stroke risk outweighs any bleeding concern, and FXIa inhibitors have not been studied in any high-bleeding-risk population
She should remain off anticoagulation permanently, since a HAS-BLED score of 4 constitutes an absolute contraindication to antithrombotic therapy
Because FXIa inhibitors reduce bleeding risk more than DOACs, she should be switched to one now, since these agents are already FDA-approved for high-risk SPAF
She represents the undertreated, high-bleeding-risk population being studied for FXIa inhibitors as an alternative to no anticoagulation, though current agents are not yet uniformly proven superior to DOACs for stroke prevention
6. Based on the totality of phase 3 evidence (OCEANIC-AF, LIBREXIA-AF pending, AZALEA-TIMI 71, LILAC-TIMI 76), how should emerging FXIa inhibitor data currently inform the new paradigm discussion for SPAF?
FXIa inhibitors have already replaced DOACs as first-line therapy for all AF patients based on consistent superiority across every completed phase 3 trial
Any paradigm shift is likely to be selective and indication-specific, favoring high-bleeding-risk or anticoagulation-ineligible patients, pending further efficacy data from ongoing trials such as LIBREXIA-AF
No FXIa inhibitor has demonstrated any bleeding advantage over DOACs, so continued investment in this drug class is not justified by current evidence
Regulatory agencies have already approved an FXIa inhibitor for broad first-line use in SPAF based on the OCEANIC-AF results
Submit
Should be Empty: